# Progel Vascular Sealant

Study · id `cardio:ct-nct01959503` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01959503](<https://clinicaltrials.gov/study/NCT01959503>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01959503

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

## Technical summary

Registry record NCT01959503. Randomized; single masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2017-01-09.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 158 participants (enrolled count; ClinicalTrials.gov record NCT01959503, source copy `cardio:ctgov-nct01959503-2017-04-10`, retrieved 2026-10-26)
- Start date: 2013-11 (registry gives no type) (ClinicalTrials.gov record NCT01959503, source copy `cardio:ctgov-nct01959503-2017-04-10`, retrieved 2026-10-26)
- Primary completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01959503, source copy `cardio:ctgov-nct01959503-2017-04-10`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01959503, source copy `cardio:ctgov-nct01959503-2017-04-10`, retrieved 2026-10-26)
- Results first posted: 2017-01-09 (ClinicalTrials.gov record NCT01959503, source copy `cardio:ctgov-nct01959503-2017-04-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01959503, source copy `cardio:ctgov-nct01959503-2017-04-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01959503-2017-04-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Progel Vascular Sealant
- Condition: Aortic Valve Stenosis
- Condition: Aneurysm of Ascending Aorta
- Condition: Aortic Valve Disorder
- Condition: Bicuspid Valve Disorder
- Intervention (Device): Progel Vascular Sealant
- Intervention (Device): Gelfoam Plus
- Lead sponsor: C. R. Bard
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Thoracic aortic aneurysm (`cardio:thoracic-aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: C. R. Bard (`cardio:org-c-r-bard`)

## Provenance

Content hash: f9f53aaf1fec1f94a3746287a1dc10e9ab640b2b57a9125a176be797b99457e3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
